Anavex Life Sciences Corp. (NASDAQ:AVXL) Reports 31-Week Efficacy Results From ANAVEX 2-73 Phase 2a Study

Anavex Life Sciences Corp. (NASDAQ:AVXL) has revealed on Wednesday at the Alzheimer’s Association International Conference (AAIC) 2016 a 31-week efficacy report about the ongoing ANAVEX 2-73 Phase 2a clinical trial in mild-to-moderate Alzheimer’s disease. 31-Week Data So far, the efficacy report shows a consistent response for all quantitative secondary endpoints, which include cognitive and functional […]